Introduction The Competition Commission of India (“CCI”) for the first time has directed divestitures of assets, before granting its final approval, in a combination relating to merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharmaceutical Industries Limited (“Sun Pharma”) (referred to as the “Transaction”) [1]. Sun Pharma and Ranbaxy are both pharmaceutical companies, engaged in the manufacture and marketing of branded generic products in various countries, including India. A notification was filed with the CCI under Section 6(2) of the Competition Act, 2002 (“Act”) read with The Competition Commission of India (Procedure in regard to the Transaction of Business relating to Combinations), 2011 (“Combination Regulations”), governing the merger control provisions in India. The Act
Share on
|
|
The Indian Competition Authority directs for the first time a divestiture of assets in a merger case (Sun Pharma / Ranbaxy)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
